Filtering by
- All Subjects: chemical engineering
- Creators: Forzani, Erica
- Resource Type: Text
Realtime understanding of one’s complete metabolic state is crucial to controlling weight and managing chronic illnesses, such as diabetes. This project represents the development of a novel breath acetone sensor within the Biodesign Institute’s Center for Bioelectronics and Biosensors. The purpose is to determine if a sensor can be manufactured with the capacity to measure breath acetone concentrations typical of various levels of metabolic activity. For this purpose, a solution that selectively interacts with acetone was embedded in a sensor cartridge that is permeable to volatile organic compounds. After 30 minutes of exposure to a range of acetone concentrations, a color change response was observed in the sensors. Requiring only exposure to a breath, these novel sensor configurations may offer non-trivial improvements to clinical and at-home measurement of lipid metabolic rate.
Underreporting of energy intake (EI) has been found to be an important consideration that interferes with accurate weight control assessment and the effective use of energy balance (EB) models in an intervention setting. To better understand underreporting, a variety of estimation approaches are developed; these include back-calculating energy intake from a closed-form of the EB model, a Kalman-filter based algorithm for recursive estimation from randomly intermittent measurements in real time, and two semi-physical identification approaches that can parameterize the extent of systematic underreporting with global/local modeling techniques. Each approach is analyzed with intervention participant data and demonstrates potential of promoting the success of weight control.
In addition, substantial efforts have been devoted to develop participant-validated models and incorporate into the Hybrid Model Predictive Control (HMPC) framework for closed-loop interventions. System identification analyses from Phase I led to modifications of the measurement protocols for Phase II, from which longer and more informative data sets were collected. Participant-validated models obtained from Phase II data significantly increase predictive ability for individual behaviors and provide reliable open-loop dynamic information for HMPC implementation. The HMPC algorithm that assigns optimized dosages in response to participant real time intervention outcomes relies on a Mixed Logical Dynamical framework which can address the categorical nature of dosage components, and translates sequential decision rules and other clinical considerations into mixed-integer linear constraints. The performance of the HMPC decision algorithm was tested with participant-validated models, with the results indicating that HMPC is superior to "IF-THEN" decision rules.